
Keywords: VLDL; VLDLR; very low density lipoprotein receptor; FDP; fibrin degradation products; HMM-FDP; high molecular mass fibrin degradation products; FpB; fibrinopeptide B; ELISA; enzyme-linked immunosorbent assay; SPR; surface plasmon resonance; RAP; receptor-associ